Images List Premium Download Classic

Restenosis

Restenosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Detection of restensosis risk in patients receiving a stent
October 12, 2017 - N°20170292965

Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level ...
Drug eluting device
Rontis Hellas S.a.
August 31, 2017 - N°20170246354

The present invention relates to a drug eluting device for preventing and treating restenosis and neointimal formation after vascular procedures and/or implantation of implants comprising an implantable or non-implantable device, such as stent, balloon or graft containing an effective amount of at least one retinoid receptors ligand as active ingredient and a coating system.
Hybrid stent and method of making
Abbott Cardiovascular Systems Inc.
August 31, 2017 - N°20170246352

A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, ...
Los Angeles Biomedical Research Institute At Harbor- Ucla Medical Center
August 24, 2017 - N°20170239257

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic ...
Cyclic polypeptides for the treatment of heart failure
Los Angeles Biomedical Research Institute At Harbor- Ucla Medical Center
August 17, 2017 - N°20170233443

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment ...
Apparatus and method for treatment of in-stent restenosis
Boston Scientific Scimed, Inc.
August 17, 2017 - N°20170231694

A catheter and catheter system can use energy tailored for remodeling and/or removal of target material proximate to a body lumen, often of stenotic material or tissue in the luminal wall of a blood vessel of a patient. An elongate flexible catheter body with a radially expendable structure may have a plurality of electrodes or other electrosurgical energy delivery ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds and methods for modulating vascular injury
The Brigham And Women's Hospital, Inc.
August 03, 2017 - N°20170216238

Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of ...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Nickel titanium oxide coated articles
The Regents Of The University Of California
July 13, 2017 - N°20170197015

This disclosure relates to an article comprising at least one substrate and at least one porous coating formed on the at least one substrate. The substrate may be a medical device, for example a nitinol stent. The porous coating may comprise a nanotubular coating. The nanotubular coating may comprise a compound of nickel, titanium and oxygen. This porous coating may ...
Stent for inhibiting restenosis and stimulating reendothelialization prepared by femtosecond laser processing and method of ...
Jeonnam Technopark
June 29, 2017 - N°20170182227

Provided are a stent in which a surface of a stent strut is treated by femtosecond laser radiation and is modified by a natural polymer and a method of preparing the stent. The stent and the preparing method may inhibit restenosis and stimulate reendothelialization.
Drug-eluting medical device
Invatec Technology Center Gmbh
June 22, 2017 - N°20170173220

The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and ...
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158698

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (i) (formula (i)) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal ...
Novel crystalline form of 5-chloro-n-(methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same
Legochem Biosciences,inc.
June 01, 2017 - N°20170152251

The present invention relates to a novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be ...
Restenosis Patent Pack
Download + patent application PDFs
Restenosis Patent Applications
Download + Restenosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Restenosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Balloon angioplasty catheter coating to encourage vessel repair and further reduce restenosis
Angioscore, Inc.
May 18, 2017 - N°20170136219

A method for treating a target vascular portion of a subject including: providing an angioplasty balloon system including a balloon carrying a first therapeutic agent and a second therapeutic agent on a surface of the balloon, wherein the first therapeutic agent is an anti-proliferative or anti-mitotic agent and the second therapeutic agent is a drug that aids in vascular healing ...
Trka kinase inhibitors, compositions and methods thereof
Msd R & D (china) Co., Ltd.
April 27, 2017 - N°20170114071

The present invention is directed to six membered heteroaryl benzamide compounds of formula (i), which are tropomyosin-related kinase (trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 27, 2017 - N°20170114056

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Trka kinase inhibitors, compositions and methods thereof
Merck Sharp & Dohme Corp.
April 20, 2017 - N°20170107204

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve ...
Devices for controlling magnetic nanoparticles to treat fluid obstructions
Pulse Therapeutics, Inc.
April 06, 2017 - N°20170095675

A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents ...
Methods and apparatus for stenting comprising enhanced embolic protection coupled with improved protections against restenosis ...
Abbott Laboratories Vascular Enterprises Limited
March 30, 2017 - N°20170086965

Apparatus and methods for stenting are provided comprising a stent attached to a porous biocompatible material that is permeable to endothelial cell ingrowth, but impermeable to release of emboli of predetermined size. Preferred stent designs are provided, as well as preferred manufacturing techniques. Apparatus and methods are also provided for use at a vessel branching. Moreover, embodiments of the present ...
Gene delivery stent using titanium oxide thin film coating and method for fabricating the same
Chonnam National University Hospital
March 23, 2017 - N°20170080131

The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells. Accordingly, late ...
Substituted pyridazines as prostacyclin receptor modulators
Arena Pharmaceuticals, Inc.
March 02, 2017 - N°20170057931

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood ...
Loading